Newsfeeds - Spark Newswire

2 minute read

Mid-Morning Market Update: Markets Open Lower; AutoNation Profit Beats Estimates

Today, 4:21 AM

Following the market opening Monday, the Dow traded down 2.31% to 33,885.81 while the NASDAQ fell 1.67% to 14,186.04. The S&P also fell, dropping 1.94% to 4,243.38.

AEHR

2 minute read

Stocks That Hit 52-Week Highs On Monday

By Benzinga Insights

Today, 4:21 AM

On Monday morning, 20 companies achieved new highs for the year.

AEHR

1 minute read

Cytokinetics Shares Gain On Positive Data From Heart Disease Candidate

By Vandana Singh

Today, 4:21 AM

Cytokinetics Incorporated (NASDAQ:CYTK) has announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM Phase 2 trial of CK-3773274 (CK-274)…

CYTK

1 minute read

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

Today, 4:21 AM

ALDX

5 minute read

Cytokinetics Announces Announces Phase 2 Clinical Trial Of CK-274 ‘Demonstrated Consistent and Clinically Meaningful Reductions in Left Ventricular Outflow Tract Gradients Within Two Weeks in Patients with Obstructive Hypertrophic Cardiomyopathy’

By Bill Haddad

Today, 4:21 AM

Phase 2 Clinical Trial of CK-274 Demonstrated Consistent and Clinically Meaningful Reductions in Left Ventricular Outflow Tract Gradients Within Two Weeks in Patients with Obstructive Hypertrophic Cardiomyopathy No

CYTK

1 minute read

FDA
News

Cytokinetics Publishes Study Titled ‘A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) (COURAGE-ALS)’ To ClinicalTrials.Gov Website

By Benzinga Newsdesk

Today, 4:21 AM

https://clinicaltrials.gov/ct2/show/NCT04944784

CYTK

2 minute read

Cytokinetics Announces Three Presentations To Occur At European Society Of Cardiology Heart Failure 2021 Congress Jun. 29

By Bill Haddad

Today, 4:21 AM

SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced three presentations at Heart Failure 2021, an International Congress of the European Society of

CYTK

1 minute read

Cytokinetics Announces Completion Of Enrollment In METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure With Reduced Ejection Fraction

By Bill Haddad

Today, 4:21 AM

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the completion of patient enrollment in METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related

CYTK

3 minute read

Uncategorized

Cytokinetics Announced Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at ACC Expo

By Charles Gross

Today, 4:21 AM

Cytokinetics, Incorporated (NASDAQ: CYTK) today announced that new findings from analyses of claims data and electronic health records related to heart failure (HF) and hypertrophic cardiomyopathy (HCM) were shared in two poster presentations at the American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21).

CYTK

32 minute read

Uncategorized

Earnings Scheduled For May 6, 2021

By Benzinga Insights

Today, 4:21 AM

Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.

AAOI